FABP3 and Niemann-Pick disease, type C1: Our data, combined with a series of clinical reports and a randomized clinical trial suggesting some efficacy of miglustat therapy in NPC1 [16], [18] begin to validate the use of FABP3 as a surrogate biomarker for treatment of NPC1.